Navigation Links
Hologic, Inc. to Host Investor Reception at the RSNA Trade Show
Date:11/20/2008

BEDFORD, Mass., Nov. 20 /PRNewswire-FirstCall/ -- Hologic, Inc. (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the Company will host a meeting for members of the investment community who will be attending the RSNA (Radiological Society of North America) trade show in Chicago.

This meeting will be held on Tuesday, December 2, 2008, at McCormick Place from 8:00 - 10:00 AM (Central Time) and will include a presentation by members of Hologic's management team.

Interested participants may listen to the call (listen mode only) by dialing 800-260-8140 or 617-614-3672, password: 38598533 at 7:50 AM (Central Time) and referencing the Hologic Investor Meeting. This call is expected to last approximately thirty minutes. For those unable to participate in the live broadcast, a replay will be available one hour after the call ends through January 6, 2009 at 888-286-8010 or 617-801-6888 (pass code 92177800).

The Company will also provide a live webcast of the call. Interested participants may access the webcast at the Company's website at www.hologic.com. A replay of the call will be archived on the Company's website.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer,
'/>"/>

SOURCE Hologic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
2. Hologic, Inc. to Release Second Quarter Fiscal 2008 Operating Results Thursday, May 1st Before Market Opens
3. Hologic, Inc. to Release First Quarter Fiscal 2008 Operating Results Thursday, January 31st Before Market Opens
4. Varian, Inc. CEO to Speak at the Nasdaq OMX 22nd Investor Program
5. Trinity Biotech Investor Group Initiates Campaign of ADR Conversion to Force a Special Meeting of Shareholders
6. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
7. Pharmasset to Present at Two Upcoming Investor Conferences
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
11. VIA Pharmaceuticals Announces Upcoming Investor Conference Presentations

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...acy endpoint has been met for patients with advanc..., QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - A...he "Company"), a global biopharmaceutical company ...nnounced positive efficacy data from a Phase 2 stu...AEZS-108 (formerly AN-152), in patients with advan...
(Date:11/24/2009)... 24, 2009 Arena Pharmace...hat the company is scheduled to present at the Pip...ecember 1, 2009 at 11:30 a.m. Eastern Time (8:30 a...New York City. Jack Lief, Arena,s President and Ch...overview of the company, including its clinical de...
(Date:11/24/2009)...am Connects Customers with Partners Validated to P...tek Products , Ottawa, ON...ding provider of products for biological sample co...ounced its new global partner program. The program... partner community and is designed to help partner...
(Date:11/23/2009)...9 In a provocative new study, a University of Uta...sions the major cause of global warming cannot b...or society builds the equivalent of one new nuclea...at there will be any substantial near-term departu...ioxide emission rates," says the new paper by Tim ...
Breaking Biology Technology:AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4
...6 Zounds Hearing, a unique manufacturing,and reta...th state-of-the-art,fidelity, price point and prof...sistive listening devices (ALDs) in an effort to a...s are now available in all of the Zounds Hearing,C...8. And, from November 26,2008, through December 7...
... 26 Ceregene, Inc., a biopharmaceutical,company, ...controlled Phase 2,trial of CERE-120 in 58 patient...d not demonstrate an appreciable difference betwee...he control group. Both groups showed an approximat...ary endpoint (Unified,Parkinson,s Disease Rating S...
...Nov. 26 Covaris Incorporated today,announced that... the shipment,of its 500th instrument unit and con...o accommodate this rapid business growth, Covaris ...nization as well as implementing a,50% expansion o...was built upon the proprietary and patented AFA(TM...
Other Biology Technology:Zounds Offers the Gift of Hearing This Holiday Season With a Range of New Products 2Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease 2Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease 3Covaris Installed Instrument Base Reaches 500 Units 2
(Date:11/25/2009)...Kent State University assistant professors recentl...ation (NSF) to continue research beneficial to und... $890,000. , Christopher Blackwood, assistant pr...was awarded grants to support two separate researc...ing Litter Decomposer Communities and Functions fr...
(Date:11/24/2009)...Lupus Research Institute (LRI) today named 12 new ....6 million, recognize innovative work across a bro...or their creativity, novelty, and potential to dri...at, and cure the complex disease of systemic lupus...ed lupus researchers across the nation and include...
(Date:11/24/2009)...ts that keep weakened and flabby arteries from col...months, those stents are no longer needed -- once ...sary. Previously, doctors had no choice but to lea...l Aviv University,s Department of Biomedical Engin...atform that carries drugs where they,re needed, th...
Breaking Biology News(10 mins):Kent State University professors focus research on the environment with grants totaling $890,000 2Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3A coating for life 2Autism Support Network Launches Enhanced Features Adds Thousands of New Members Globally 57318 1Autism Support Network Launches Enhanced Features Adds Thousands of New Members Globally 57318 2Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 1Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 2Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 3Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 4Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz Lamivudine and Tenofovir Disoproxil Fumarate Tablets 57314 1Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz Lamivudine and Tenofovir Disoproxil Fumarate Tablets 57314 2
...uman immunodeficiency virus (HIV-1) molecular mach...functionally-specialized layers, according to a st...ia San Diego (UCSD) Antiviral Research Center (AVR...ology. , The unprecedented genetic diversity an... efforts to eradicate the global HIV/AIDS epidemic...
...uld More Than Double its Current Revenue, Stream...care Industry, SAN JOSE, Calif., Nov. 2 Titanium...ing biometric and security,solutions provider, ann...tent to acquire China Medical Systems (OTC: CHSY),...ching, developing and marketing of specialized,sof...
...d streams in remote parts of the UK, southern Scan...singly stained brown by dissolved organic matter. ...rnational team, led by researchers from UCL (Unive...tection Agency (EPA), demonstrates that the colour...l, pre-industrial state following a decline in the...
Other Biology News:Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 2Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 3Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 4Don't judge a brook by its color -- brown waters are more natural 2
...Adept CE 4100 high pressure dual piston pumps, eac...nts. The ground breaking WaveQuest UV/Visible ult...ity. The WaveQuest provides a trustworthy altern... superior stability . Hence only one detector is ...
...ples may be carried out using this high pressure s...System control and data processing is provided by ...legant, powerful and very easy to use software ope... supplied detector is the ground breaking WaveQues...
Oligonucleotides from Thermo Scientific
Pyrex brand low actinic narrow mouth Erlenmeyer flask, Pyrex ST 27 stopper from Sigma-Aldrich
Biology Products: